



Innovative Formulation Strategies for Solid Dispersions: Overcoming Challenges in Enhancing Solubility of BCS Class 2 Compounds

Mr. Somesh Rothe¹, Mr. Rahul Kalwe², Dr. Bhaskar Mohite³,

Dr. Ajaz Sheikh⁴, Dr. Kailash Biyani⁵

Anuradha College of Pharmacy, Chickhlia, Maharashtra, India

Abstract: Controlled release tablets play a pivotal role in pharmaceutical formulations, offering targeted drug delivery and improved patient compliance. This review explores innovative approaches for modulating gastrointestinal absorption to achieve controlled and sustained release from tablets. The introduction provides a brief overview of controlled release tablets, emphasizing the significance of influencing drug absorption for achieving therapeutic efficacy. The objective is to highlight the need for innovative approaches in modulating gastrointestinal absorption, addressing current challenges in achieving controlled release. Physiological considerations in gastrointestinal absorption are examined, including the structure and function of the stomach and intestines, along with factors influencing drug absorption in different regions. Challenges in achieving controlled release, such as variability in gastric emptying times and pH-dependent solubility issues, are discussed. Conventional methods, such as enteric coatings and modified-release formulations, are explored alongside their limitations, emphasizing the incomplete control over drug release and the lack of adaptability to individual patient variations. The review then delves into novel strategies, including bioresponsive materials, carrier systems, and prodrug approaches, showcasing their potential in overcoming challenges associated with conventional methods. Technological advances, such as microfabrication techniques and 3D printing in gastrointestinal drug delivery, are examined, offering insights into customized tablets for controlled release. In vitro and in vivo assessment methods are detailed, covering simulated gastric and intestinal conditions, tools for predicting in vivo performance, and the use of animal models and clinical trials. The review concludes with an exploration of challenges and future perspectives, addressing biopharmaceutical variability and regulatory considerations. The findings provide a structured approach for formulators, researchers, and pharmaceutical scientists in advancing controlled release tablet development, paving the way for personalized and effective drug delivery.

Keywords: controlled release tablets, gastrointestinal absorption, innovative approaches, drug delivery, sustained release, novel strategies, technological advances, personalized.

REFERENCES

- [1]. Asim, M. H., Nazir, I., Jalil, A., Laffleur, F., Matusczak, B., & Bernkop-Schnürch, A. (2020). Per-6-Thiolated Cyclodextrins: A Novel Type of Permeation Enhancing Excipients for BCS Class IV Drugs. *ACS applied materials & interfaces*, 12(7), 7942–7950. <https://doi.org/10.1021/acsami.9b21335>
- [2]. Kano, T., Kakinuma, C., Wada, S., Morimoto, K., & Ogihara, T. (2011). Enhancement of drug solubility and absorption by copolymers of 2-methacryloyloxyethyl phosphorylcholine and n-butyl methacrylate. *Drug metabolism and pharmacokinetics*, 26(1), 79–86. <https://doi.org/10.2133/dmpk.dmpk-10-rg-070>
- [3]. Liu, L., Zou, D., Zhang, Y., Zhang, Q., Feng, Y., Guo, Y., Liu, Y., Zhang, X., Cheng, G., Wang, C., Zhang, Y., Zhang, L., Wu, L., Chang, L., Su, X., Duan, Y., Zhang, Y., & Liu, M. (2020). Pharmaceutical salts/cocrystals of enoxacin with dicarboxylic acids: Enhancing in vitro antibacterial activity of enoxacin by improving the solubility and permeability. *European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik.V*, 154, 62–73. <https://doi.org/10.1016/j.ejpb.2020.06.018>

- [4]. Pérez-Carreón, K., Martínez, L. M., Videá, M., Cruz-Angeles, J., Gómez, J., & Ramírez, E. (2023). Effect of Basic Amino Acids on Folic Acid Solubility. *Pharmaceutics*, 15(11), 2544. <https://doi.org/10.3390/pharmaceutics15112544>
- [5]. Deshmukh, D. D., Nagilla, R., Ravis, W. R., & Betageri, G. V. (2010). Effect of dodecylmaltoside (DDM) on uptake of BCS III compounds, tiludronate and cromolyn, in Caco-2 cells and rat intestine model. *Drug delivery*, 17(3), 145–151. <https://doi.org/10.3109/10717541003604882>
- [6]. Dave, V. S., Gupta, D., Yu, M., Nguyen, P., & Varghese Gupta, S. (2017). Current and evolving approaches for improving the oral permeability of BCS Class III or analogous molecules. *Drug development and industrial pharmacy*, 43(2), 177–189. <https://doi.org/10.1080/03639045.2016.1269122>
- [7]. Saha, P., & Kou, J. H. (2000). Effect of solubilizing excipients on permeation of poorly water-soluble compounds across Caco-2 cell monolayers. *European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik.V*, 50(3), 403–411. [https://doi.org/10.1016/s0939-6411\(00\)00113-2](https://doi.org/10.1016/s0939-6411(00)00113-2)
- [8]. Heinen, C., Reuss, S., Saaler-Reinhardt, S., & Langguth, P. (2013). Mechanistic basis for unexpected bioavailability enhancement of polyelectrolyte complexes incorporating BCS class III drugs and carrageenan. *European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik.V*, 85(1), 26–33. <https://doi.org/10.1016/j.ejpb.2013.03.010>
- [9]. Xia, B., Heimbach, T., Lin, T. H., Li, S., Zhang, H., Sheng, J., & He, H. (2013). Utility of physiologically based modeling and preclinical in vitro/in vivo data to mitigate positive food effect in a BCS class 2 compound. *AAPS PharmSciTech*, 14(3), 1255–1266. <https://doi.org/10.1208/s12249-013-0018-2>
- [10]. Abdelkader, A., Nallbati, L., & Keck, C. M. (2023). Improving the Bioactivity of Norfloxacin with Tablets Made from Paper. *Pharmaceutics*, 15(2), 375. <https://doi.org/10.3390/pharmaceutics15020375>
- [11]. Kristin, F., René, H., Boontida, M., Buraphacheep, J. V., Maximilian, A., Johanna, M., & Peter, L. (2017). Dissolution and dissolution/permeation experiments for predicting systemic exposure following oral administration of the BCS class II drug clarithromycin. *European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences*, 101, 211–219. <https://doi.org/10.1016/j.ejps.2017.02.003>
- [12]. Bertoni, S., Albertini, B., & Passerini, N. (2020). Different BCS Class II Drug-Gelucire Solid Dispersions Prepared by Spray Congealing: Evaluation of Solid State Properties and In Vitro Performances. *Pharmaceutics*, 12(6), 548. <https://doi.org/10.3390/pharmaceutics12060548>
- [13]. Zvonar, A., Berginc, K., Kristl, A., & Gasperlin, M. (2010). Microencapsulation of self-microemulsifying system: improving solubility and permeability of furosemide. *International journal of pharmaceutics*, 388(1-2), 151–158. <https://doi.org/10.1016/j.ijpharm.2009.12.055>
- [14]. Tong, H. H., Du, Z., Wang, G. N., Chan, H. M., Chang, Q., Lai, L. C., Chow, A. H., & Zheng, Y. (2011). Spray freeze drying with polyvinylpyrrolidone and sodium caprate for improved dissolution and oral bioavailability of oleanolic acid, a BCS Class IV compound. *International journal of pharmaceutics*, 404(1-2), 148–158. <https://doi.org/10.1016/j.ijpharm.2010.11.027>
- [15]. Payghan, S., Payghan, V., Nangare, K., Dahiwade, L., Khavane, K., & Phalke, R. (2022). Preparation and Characterization of OrlistatBionanocomposites Using Natural Carriers. *Turkish journal of pharmaceutical sciences*, 19(2), 168–179. <https://doi.org/10.4274/tjps.galenos.2021.71363>
- [16]. Wahlang, B., Pawar, Y. B., & Bansal, A. K. (2011). Identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model. *European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik.V*, 77(2), 275–282. <https://doi.org/10.1016/j.ejpb.2010.12.006>
- [17]. Kesisoglou, F., Xie, I. H., Manser, K., Wu, Y., Hardy, I., & Fitzpatrick, S. (2014). Suitability of a minipig model in assessing clinical bioperformance of matrix and multiparticulate extended-release formulations for a BCS class III Drug development candidate. *Journal of pharmaceutical sciences*, 103(2), 636–642. <https://doi.org/10.1002/jps.23837>

- [18]. Ates, M., Kaynak, M. S., & Sahin, S. (2016). Effect of permeability enhancers on paracellular permeability of acyclovir. *The Journal of pharmacy and pharmacology*, 68(6), 781–790. <https://doi.org/10.1111/jphp.12551>
- [19]. Prabhu, P., & Patravale, V. (2016). Dissolution enhancement of atorvastatin calcium by co-grinding technique. *Drug delivery and translational research*, 6(4), 380–391. <https://doi.org/10.1007/s13346-015-0271-x>
- [20]. Prabhu, P., & Patravale, V. (2016). Dissolution enhancement of atorvastatin calcium by co-grinding technique. *Drug delivery and translational research*, 6(4), 380–391. <https://doi.org/10.1007/s13346-015-0271-x>
- [21]. Pujara, N., Giri, R., Wong, K. Y., Qu, Z., Rewatkar, P., Moniruzzaman, M., Begun, J., Ross, B. P., McGuckin, M., & Popat, A. (2021). pH - Responsive colloidal carriers assembled from β -lactoglobulin and Epsilon poly-L-lysine for oral drug delivery. *Journal of colloid and interface science*, 589, 45–55. <https://doi.org/10.1016/j.jcis.2020.12.054>
- [22]. Linn, M., Collnot, E. M., Djuric, D., Hempel, K., Fabian, E., Kolter, K., & Lehr, C. M. (2012). Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo. *European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences*, 45(3), 336–343. <https://doi.org/10.1016/j.ejps.2011.11.025>
- [23]. Nijhawan, M., Santhosh, A., Babu, P. R., & Subrahmanyam, C. V. (2014). Solid state manipulation of lornoxicam for cocrystals--physicochemical characterization. *Drug development and industrial pharmacy*, 40(9), 1163–1172. <https://doi.org/10.3109/03639045.2013.804834>
- [24]. He, X., Wei, Y., Wang, S., Zhang, J., Gao, Y., Qian, S., Pang, Z., & Heng, W. (2022). Improved Pharmaceutical Properties of Honokiol via Salification with Meglumine: an Exception to Oft-quoted ApK_a Rule. *Pharmaceutical research*, 39(9), 2263–2276. <https://doi.org/10.1007/s11095-022-03335-6>
- [25]. Beloqui, A., Solinís, M. Á., Gascón, A. R., del Pozo-Rodríguez, A., des Rieux, A., & Préat, V. (2013). Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. *Journal of controlled release : official journal of the Controlled Release Society*, 166(2), 115–123. <https://doi.org/10.1016/j.jconrel.2012.12.021>
- [26]. Wu, L., Qiao, Y., Wang, L., Guo, J., Wang, G., He, W., Yin, L., & Zhao, J. (2015). A Self-microemulsifying Drug Delivery System (SMEDDS) for a Novel Medicative Compound Against Depression: a Preparation and Bioavailability Study in Rats. *AAPS PharmSciTech*, 16(5), 1051–1058. <https://doi.org/10.1208/s12249-014-0280-y>
- [27]. Patel, K., Doddapaneni, R., Patki, M., Sekar, V., Bagde, A., & Singh, M. (2019). Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells. *AAPS PharmSciTech*, 20(3), 135. <https://doi.org/10.1208/s12249-019-1332-0>
- [28]. Nkansah, P., Antipas, A., Lu, Y., Varma, M., Rotter, C., Rago, B., El-Kattan, A., Taylor, G., Rubio, M., & Litchfield, J. (2013). Development and evaluation of novel solid nanodispersion system for oral delivery of poorly water-soluble drugs. *Journal of controlled release : official journal of the Controlled Release Society*, 169(1-2), 150–161. <https://doi.org/10.1016/j.jconrel.2013.03.032>
- [29]. Vadher, A. H., Parikh, J. R., Parikh, R. H., & Solanki, A. B. (2009). Preparation and characterization of co-grounded mixtures of aceclofenac and neusilin US2 for dissolution enhancement of aceclofenac. *AAPS PharmSciTech*, 10(2), 606–614. <https://doi.org/10.1208/s12249-009-9221-6>
- [30]. Deshmukh, D. D., Ravis, W. R., & Betageri, G. V. (2008). Improved delivery of cromolyn from oral proliposomal beads. *International journal of pharmaceutics*, 358(1-2), 128–136. <https://doi.org/10.1016/j.ijpharm.2008.02.026>
- [31]. Tian, Y., Booth, J., Meehan, E., Jones, D. S., Li, S., & Andrews, G. P. (2013). Construction of drug-polymer thermodynamic phase diagrams using Flory-Huggins interaction theory: identifying the relevance of temperature and drug weight fraction to phase separation within solid dispersions. *Molecular pharmaceutics*, 10(1), 236–248. <https://doi.org/10.1021/mp300386v>
- [32]. Rachmawati, H., Pradana, A. T., Safitri, D., & Adnyana, I. K. (2017). Multiple Functions of D- α -Tocopherol Polyethylene Glycol 1000 Succinate (TPGS) as Curcumin Nanoparticle Stabilizer In Vivo Kinetic Profile

- and Anti-Ulcerative Colitis Analysis in Animal Model. *Pharmaceutics*, 9(3), 24. <https://doi.org/10.3390/pharmaceutics9030024>
- [33]. Lohani, S., Cooper, H., Jin, X., Nissley, B. P., Manser, K., Rakes, L. H., Cummings, J. J., Fauty, S. E., & Bak, A. (2014). Physicochemical properties, form, and formulation selection strategy for a biopharmaceutical classification system class II preclinical drug candidate. *Journal of pharmaceutical sciences*, 103(10), 3007–3021. <https://doi.org/10.1002/jps.24088>
- [34]. Himawan, A., Djide, N. J. N., Mardikasari, S. A., Utami, R. N., Arjuna, A., Donnelly, R. F., & Permana, A. D. (2022). A novel in vitro approach to investigate the effect of food intake on release profile of valsartan in solid dispersion-floating gel in-situ delivery system. *European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences*, 168, 106057. <https://doi.org/10.1016/j.ejps.2021.106057>
- [35]. Chen, T., Li, C., Li, Y., Yi, X., Wang, R., Lee, S. M., & Zheng, Y. (2017). Small-Sized mPEG-PLGA Nanoparticles of Schisantherin A with Sustained Release for Enhanced Brain Uptake and Anti-Parkinsonian Activity. *ACS applied materials & interfaces*, 9(11), 9516–9527. <https://doi.org/10.1021/acsami.7b01171>